Boothwyn Pharmacy Semaglutide Injection Recall for Subpotent Drug (High-Risk)
Boothwyn Pharmacy LLC issued a nationwide recall of 186 vials of Semaglutide 2.5 mg/mL injection, 0.8 mL, on July 9, 2025. The FDA enforcement report classifies the recall as Class II with a high hazard level. Consumers and healthcare providers should stop using the product immediately and follow guidance from Boothwyn Pharmacy or a healthcare provider.